A Research Agenda for Malaria Eradication: Vaccines

The Malaria Eradication Research Agenda (malERA) Consultative Group on Vaccines present a research and development agenda to provide the tools to create vaccines that may be used during malaria eradication.

• Publication year

  2011

• Venue

  PLoS Medicine

• Publication date

  2011-01-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1371/journal.pmed.1000398PMID 21311586PMCID 3026701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Research Agenda for Malaria Eradication: Monitoring, Evaluation, and Surveillance

  2011cited by this paper
• A Research Agenda for Malaria Eradication: Vector Control

  2011cited by this paper
• A Research Agenda for Malaria Eradication: Basic Science and Enabling Technologies

  2011cited by this paper
• A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics

  2011cited by this paper
• The Role of Research in Viral Disease Eradication and Elimination Programs: Lessons for Malaria Eradication

  2011cited by this paper
• A Research Agenda for Malaria Eradication: Modeling

  2011cited by this paper
• A Research Agenda for Malaria Eradication: Drugs

  2011cited by this paper
• A Research Agenda for Malaria Eradication: Cross-Cutting Issues for Eradication

  2011cited by this paper
• Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

  2010cited by this paper
• Thrombocytopenia in Plasmodium falciparum, Plasmodium vivax and mixed infection malaria: A study from Bikaner (Northwestern India)

  2010cited by this paper
• Plasmodium knowlesi from archival blood films: Further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo

  2009cited by this paper
• A Potent Malaria Transmission Blocking Vaccine Based on Codon Harmonized Full Length Pfs48/45 Expressed in Escherichia coli

  2009cited by this paper
• Role of injectable and oral polio vaccines in polio eradication

  2009cited by this paper
• Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India.

  2009cited by this paper
• New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance

  2009cited by this paper
• Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’

  2009cited by this paper
• Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51

  2008cited by this paper
• What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines

  2008cited by this paper
• Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis

  2008cited by this paper
• Effective induction of high-titer antibodies by viral vector vaccines

  2008cited by this paper
• Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening.

  2008cited by this paper
• Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice

  2008cited by this paper
• Sex in Plasmodium: a sign of commitment.

  2008cited by this paper
• Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya

  2008cited by this paper
• Antibodies Targeting the PfRH1 Binding Domain Inhibit Invasion of Plasmodium falciparum Merozoites

  2008cited by this paper
• Plasmodium vivax Invasion of Human Erythrocytes Inhibited by Antibodies Directed against the Duffy Binding Protein

  2007cited by this paper
• Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.

  2007cited by this paper
• Maternal and neonatal tetanus.

  2007cited by this paper
• Vivax malaria: neglected and not benign.

  2007cited by this paper
• Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen

  2007cited by this paper
• Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum.

  2006cited by this paper
• Global measles elimination

  2006cited by this paper
• Plasmodium vivax Malaria

  2005cited by this paper
• Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

  2005cited by this paper
• Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study.

  2005cited by this paper
• Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data

  2005cited by this paper
• Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.

  2005cited by this paper
• Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.

  2004cited by this paper
• Migration through host cells activates Plasmodium sporozoites for infection

  2002cited by this paper
• Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis

  2002cited by this paper
• Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies.

  2002cited by this paper
• Function of Region I and II Adhesive Motifs ofPlasmodium falciparum Circumsporozoite Protein in Sporozoite Motility and Infectivity*

  2002cited by this paper
• Transmission blocking malaria vaccines.

  2001cited by this paper
• The neglected burden of Plasmodium vivax malaria.

  2001cited by this paper
• DDT house spraying and re-emerging malaria.

  2000cited by this paper
• Antibodies against the Plasmodium falciparum Receptor Binding Domain of EBA-175 Block Invasion Pathways That Do Not Involve Sialic Acids

  2000cited by this paper
• The A‐domain and the thrombospondin‐related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands

  1999cited by this paper
• TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites.

  1997cited by this paper
• Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum.

  1994cited by this paper
• The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites.

  1992cited by this paper
• Principles and lessons from the smallpox eradication programme.

  1987cited by this paper

• Asymptomatic school children and adults are important for the human infectious reservoir for Plasmodium falciparum malaria in an area of low endemicity in The Gambia

  2025cites this paper
• Efficacy of Three Vaccine Regimens Against Infectious Hematopoietic Necrosis Virus Transmission Potential in Rainbow Trout

  2025cites this paper
• Quantification of Plasmodium falciparum: validation of quantitative polymerase chain reaction assays for detection of parasites in controlled human malaria infection studies

  2025cites this paper
• Complete attenuation of Plasmodium falciparum sporozoites by atovaquone–proguanil

  2025cites this paper
• Phosphorylation in the Plasmodium falciparum Proteome: A Meta-Analysis of Publicly Available Data Sets

  2024cites this paper
• Facilitating the use of the target product profile in academic research: a systematic review

  2024cites this paper
• Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development

  2024cites this paper
• Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase in Plasmodium vivax

  2024cites this paper
• Ifakara MasterClasses: lessons from leading experts on the battle against malaria.

  2023cites this paper
• An In Silico Analysis of Malaria Pre-Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate Variants and Epitopes

  2022cites this paper
• Sub-national tailoring of malaria interventions in Mainland Tanzania: simulation of the impact of strata-specific intervention combinations using modelling

  2022cites this paper
• New Protein Settings to Support in vivo Antimalarial Activity in Plasmodium berghei Infected Mice after Garlic-Arteether Therapy

  2022cites this paper
• RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

  2022cites this paper
• Design and development of a self-assembling protein nanoparticle displaying PfHAP2 antigenic determinants recognized by natural acquired antibodies

  2022cites this paper
• Cryopreservation of Plasmodium Sporozoites

  2022cites this paper
• Projecting Malaria Incidence Based on Climate Change Modeling Approach: A Systematic Review

  2022cites this paper
• Differential Incidence of Malaria in Neighboring Villages in a High-Transmission Setting of Southern Mali

  2022cites this paper
• Untangling population structure and genetic diversity of reticulocyte binding protein 2b (PvRBP2b) erythrocytic stage vaccine candidate in worldwide Plasmodium vivax isolates

  2022cites this paper
• Quantifying Reductions in Plasmodium falciparum Infectivity to Mosquitos: A Sample Size Calculator to Inform Clinical Trials on Transmission-Reducing Interventions

  2022cites this paper
• Optimization of the heterologous expression and purification of Plasmodium falciparum generative cell specific 1 in Escherichia coli.

  2022cites this paper
• How can we develop an effective subunit vaccine to achieve successful malaria eradication?

  2021cites this paper
• Genetic Diversity of Plasmodium vivax Cysteine-Rich Protective Antigen (PvCyRPA) in Field Isolates from Five Different Areas of the Brazilian Amazon

  2021cites this paper
• Incidence of Plasmodium Falciparum Malaria Infection in 6-month- to 45-year-olds on Bioko Island, Equatorial Guinea.

  2021cites this paper
• Optimal control analysis of hepatocytic-erythrocytic dynamics of Plasmodium falciparum malaria

  2021cites this paper
• A new Plasmodium falciparum field isolate from Benin in continuous culture: Infectivity of fresh-produced and cryopreserved gametocytes to Anopheles gambiae

  2021cites this paper
• Molecular interactions between parasite and mosquito during midgut invasion as targets to block malaria transmission

  2021cites this paper
• Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination

  2021cites this paper
• Standard Membrane Feeding Assay for Malaria Transmission Studies.

  2021cites this paper
• Malaria research in Australia: looking through the lens of the past towards the future.

  2021cites this paper
• Antibody Responses to Crude Gametocyte Extract Predict Plasmodium falciparum Gametocyte Carriage in Kenya

  2021cites this paper
• Incidence of Plasmodium falciparum malaria infection in 6-month to 45-year-olds on selected areas of Bioko Island, Equatorial Guinea

  2021cites this paper
• Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen

  2020cites this paper
• Mapping of safe and early chemo-attenuated live Plasmodium falciparum immunization identifies immune signature of vaccine efficacy

  2020cites this paper
• Antibody combinations targeting the essential antigens CyRPA, RH5 and MSP-119 potently neutralize Plasmodium falciparum clinical isolates from India and Africa.

  2020cites this paper
• An Arms Race Against Disinfectant Resistance

  2020cites this paper
• Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.

  2020cites this paper
• Future use-cases of vaccines in malaria control and elimination

  2020cites this paper
• Malaria vaccines since 2000: progress, priorities, products

  2020cites this paper
• Dissection-independent production of a protective whole-sporozoite malaria vaccine

  2020cites this paper
• Sexual forms obtained in a continuous in vitro cultured Colombian strain of Plasmodium falciparum (FCB2)

  2020cites this paper
• Identification, molecular characterization and expression of aminopeptidase N-1 (APN-1) from Anopheles stephensi in SF9 cell line as a candidate molecule for developing a vaccine that interrupt malaria transmission

  2020cites this paper
• Designing a multi-epitope vaccine against blood-stage of Plasmodium falciparum by in silico approaches.

  2020cites this paper
• Malaria

  2020cites this paper
• Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8+ T Cell Responses but Differ in Capacity to Induce CD4+ T Cell Responses and Antibody Responses

  2020cites this paper
• Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein

  2020cites this paper
• New dimensions in the field of antimalarial research against malaria resurgence.

  2019cites this paper
• High Plasmodium infection intensity in naturally infected malaria vectors in Africa

  2019cites this paper
• Investigating the impact of enhanced community case management and monthly screening and treatment on the transmissibility of malaria infections in Burkina Faso: study protocol for a cluster-randomised trial

  2019cites this paper
• Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice

  2019cites this paper
• Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi

  2019cites this paper
• Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice

  2019cites this paper
• Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence.

  2019cites this paper
• The Antibody Response to Plasmodium falciparum: Cues for Vaccine Design and the Discovery of Receptor-Based Antibodies.

  2019cites this paper
• Two-Faced Immunity? The Evidence for Antibody Enhancement of Malaria Transmission.

  2019cites this paper
• Streamlined SMFA and mosquito dark-feeding regime significantly improve malaria transmission-blocking assay robustness and sensitivity

  2019cites this paper
• The Expression Of Recombinant Plasmodium Falciparum Sexual-Stage Proteins And Assessment Of Naturally Acquired Transmission-Blocking Immunity

  2019cites this paper
• Immunoepidemiology of Plasmodium falciparum malaria

  2019cites this paper
• How vaccines work: immune effector mechanisms and designer vaccines

  2019cites this paper
• Whole-blood transcriptomic signatures induced during immunization by chloroquine prophylaxis and Plasmodium falciparum sporozoites

  2019cites this paper
• Chimeric Murine Polyomavirus Virus-Like Particles Induce Plasmodium Antigen-Specific CD8+ T Cell and Antibody Responses

  2019cites this paper
• Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults

  2018cites this paper
• Identification, Molecular Characterization, and In Silico Structural Analysis of Carboxypeptidase B2 of Anopheles stephensi

  2018cites this paper
• Immune Responses in Malaria Transmission

  2018cites this paper
• On the Evolution and Function of Plasmodium vivax Reticulocyte Binding Surface Antigen (pvrbsa)

  2018cites this paper
• Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination

  2018cites this paper
• Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax

  2018cites this paper
• Analysis of genetic diversity and population structure of gene encoding cell-traversal protein for ookinetes and sporozoites (CelTOS) vaccine candidate antigen in global Plasmodium falciparum populations.

  2018cites this paper
• CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria

  2018cites this paper
• In Silico Study Reveals How E64 Approaches, Binds to, and Inhibits Falcipain-2 of Plasmodium falciparum that Causes Malaria in Humans

  2018cites this paper
• Mathematical model for the in-host malaria dynamics subject to malaria vaccines

  2018cites this paper
• Reduced-representation sequencing identifies small effective population sizes of Anopheles gambiae in the north-western Lake Victoria basin, Uganda

  2018cites this paper
• Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children

  2018cites this paper
• Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study

  2018cites this paper
• Statistical Methods for Standard Membrane-Feeding Assays to Measure Transmission Blocking or Reducing Activity in Malaria

  2018cites this paper
• Immunization efficacy of cryopreserved genetically attenuated Plasmodium berghei sporozoites

  2018cites this paper
• Navigating the immuno-epidemiology of malaria: Potential metrics for surveillance and cluster randomised trials

  2018cites this paper
• Assessment of Antibodies Induced by Multivalent Transmission-Blocking Malaria Vaccines

  2018cites this paper
• Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.

  2018cites this paper
• Deposited in DRO : 11 January 2018 Version of attached

  2018cites this paper
• Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice

  2018cites this paper
• Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice

  2018cites this paper
• Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication

  2018cites this paper
• Enteroparasite and vivax malaria co-infection on the Brazil-French Guiana border: Epidemiological, haematological and immunological aspects

  2018cites this paper
• Vaccines against malaria—still a long way to go

  2017cites this paper
• The potential use of melatonin to treat protozoan parasitic infections: A review.

  2017cites this paper
• Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.

  2017cites this paper
• Characterization of Pb51 in Plasmodium berghei as a malaria vaccine candidate targeting both asexual erythrocytic proliferation and transmission

  2017cites this paper
• Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development

  2017cites this paper
• malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication

  2017cites this paper
• The fibrinogen-like domain of FREP1 protein is a broad-spectrum malaria transmission-blocking vaccine antigen

  2017cites this paper
• Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein in Pregnant Women Are Associated with Higher Birth Weight in a Multicenter Study

  2017cites this paper
• Natural immune response to Plasmodium vivax alpha-helical coiled coil protein motifs and its association with the risk of P. vivax malaria

  2017cites this paper
• Domestic trends in malaria research and development in China and its global influence

  2017cites this paper
• Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate

  2017cites this paper
• Functional Characterization and Comparison of Plasmodium falciparum Proteins as Targets of Transmission-blocking Antibodies

  2017cites this paper
• Steady progress toward a malaria vaccine

  2017cites this paper
• Magnetically-enabled biomarker extraction and delivery system: towards integrated ASSURED diagnostic tools.

  2017cites this paper
• Maximizing research study effectiveness in malaria elimination settings: a mixed methods study to capture the experiences of field-based staff

  2017cites this paper
• malERA: An updated research agenda for malaria elimination and eradication

  2017cites this paper
• Limited genetic diversity in the global Plasmodium vivax Cell traversal protein of Ookinetes and Sporozoites (CelTOS) sequences; implications for PvCelTOS-based vaccine development.

  2017cites this paper